Thursday, December 6, 2012
Thursday, March 29, 2012
Recently INTECH has published an online book "Recent Advances in Research on the Human Placenta" which provides a comprehensive and updated overview of the human placenta in current scenario. Interested readers can read it online or may download the book (in pdf format) - its free and no registration required.
This book contains the total of 19 chapters, each of which is written by one or several experts in the corresponding field. The objective of this book is to provide a comprehensive and most updated overview of the human placenta, including current advances and future directions in the early detection, recognition, and management of placental abnormalities as well as the most common placental structure and functions, abnormalities, toxicology, infections, and pathologies. It also includes a highly controversial topic, therapeutic applications of the human placenta. A collection of articles presented by active investigators provides a clear update in the area of placental research for medical students, nurse practitioners, practicing clinicians, and biomedical researchers in the fields of obstetrics, pediatrics, family practice, genetics, and others who may be interested in human placentas.
Dr. Jing Zheng
Obstetrics and Gynecology
InTech, March, 2012
Hard cover, 428 pages
The Indian scientists Piyali Datta Chakraborty and Debasish Bhattacharyya have also contributed in this book with their work "Aqueous Extract of Human Placenta as a therapeutic-agent" (Chapter 4).
For Further details, refer to:
Friday, November 11, 2011
U.S. drug regulators have for the first time approved a therapy that uses cells of human blood from the placenta and the umbilical cord to treat people with blood-forming disorders or cancer.
The Food and Drug Administration (USA) on Thursday (Oct 10, 2011) licensed HEMACORD, manufactured by the New York Blood Center (NYBC), a therapy that contains self-recreating cells similar to stem cells from human cord blood. This therapy is known as hematopoietic progenitor cells-cord (HPC-C) cell therapy.
Those blood-forming types of cells, known as progenitor cells, are infused into patients and make their way to bone marrow, where they divide and mature. As they move into the bloodstream, they can help build new blood cells or restore their capacities, including immune function.
Hemacord is approved for use in blood-restoring stem cell transplants, which can use cells from three sources: cords, bone marrow and peripheral blood, the flowing blood that circulates through the body.
"We have been using cord blood for years," said Dr. Machi Scaradavou, medical director of the NYBC's National Cord Blood Program." Recently, FDA decided that it needs to be licensed and this is the first cord blood product and stem cell product to be licensed."
In 2009, the FDA guided manufacturers of such therapies to submit by Oct. 20 applications either for a license or for an approval as an investigational new drug. National Cord Blood Program is the first to get FDA's nod, Scaradavou said.
"The use of cord blood hematopoietic (blood-forming) progenitor cell therapy offers potentially life-saving treatment options," said Dr. Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.
Saturday, October 1, 2011
To give a refreshing change to the look & feel of our this blog, we have used Dynamic Views which uses AJAX, HTML5 and CSS3 technology. This feature now offers the visitors of this blog/site the ability to present our information in innovative ways - the dynamic way.
The flavors you can test are:
- Classic - A modern twist on a traditional layout, with infinite scrolling and images that load as you go
- Flipcard - The photos of the blog are tiled across the page and flip to reveal the post title
- Magazine - A clean, elegant editorial style layout
- Mosaic - A mosaic mix of different sized images and text
- Sidebar - An email inbox-like view with a reading page for quick scrolling and browsing
- Snapshot - An interactive pinboard of the blog posts
- Timeslide - A horizontal view of the blog posts by time period
So click on the option "Dynamic Views" provided on the top right of the blog and get the new look & feel of this blog by testing the different modes provided - currently we have kept this new look as an optional view.
IMPT. NOTE: This feature is applicable only for modern browsers, and will not run on old browsers like Internet Explorer 6.0 (IE6.0)
Please let us know about our this new experiment with the look & feel of HPE blog.
Wednesday, September 28, 2011
For the readers of this blog we have come up with the following study recently conducted by a Korean team on the efficacy and safety of Human Placental Extract solution on fatigue. Fatigue is a common symptom, but only a few effective treatments are available. This study was supported by a grant from Unimed Pharm., INC. and was conducted at the requests of the Korea Food and Drug Administration (KFDA).
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 130875, 6 pages doi:10.1155/2012/130875
Efficacy and Safety of Human Placental Extract Solution on Fatigue: A Double-Blind, Randomized, Placebo-Controlled Study
1Department of Family Medicine, The Catholic University of Korea School of Medicine, Seocho-gu 137-701, Republic of Korea2Department of Family Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 505 Banpo-dong, Seocho-gu 137-701, Republic of Korea3Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon 443-721, Republic of Korea
A total of 315 subjects were randomly assigned to three groups: group 1 (with Unicenta solution administration), group 2 (with exclusively human placental extract administration, excluding other ingredients from the Unicenta solution), and the placebo group. Subsequently, solutions were administered for four weeks.
The fatigue recovery rate was 71.00% in group 1, 71.72% in group 2, and 44.21% in the placebo group, which show statistically significant differences between the group 1 and the placebo group (P value = 0.0002), and between group 2 and the placebo group (P value = 0.0001).
The oral human placental extract was effective in the improvement of fatigue. The adverse event frequency in the experimental groups was similar to that in the placebo group.